Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Blood Pressure Monitoring Journal Publishes Clinical Study Results Validating the Accuracy of Biospectal OptiBP™

Cuffless, optical smartphone blood pressure solution, Biospectal OptiBP furthers Biospectal's mission to democratize access and bring the power of remote patient monitoring to people and communities worldwide


News provided by

Biospectal

Aug 05, 2021, 10:05 ET

Share this article

Share toX

Share this article

Share toX

Biospectal OptiBP: The Optical Revolution in Blood Pressure Management
Biospectal OptiBP: The Optical Revolution in Blood Pressure Management
Youtube
Youtube

SAN FRANCISCO and LAUSANNE, Switzerland, Aug. 5, 2021 /PRNewswire-PRWeb/ -- Biospectal, the remote patient monitoring and biosensing software company, today announced the publication of clinical study results in Blood Pressure Monitoring Journal. Conducted by the team of Prof. Patrick Schoettker at CHUV Lausanne University hospital and the University of Lausanne UNIL in Switzerland, the study results confirm Biospectal OptiBP meets the ISO 81060-2 international protocol for accuracy for blood pressure measurement devices. The study results also reinforce the clinical accuracy of Biospectal's OptiBP software-based smartphone app solution to accurately measure blood pressure utilizing transdermal optical sensing with only a fingertip applied to the lens of a smartphone camera. The study was conducted with a cohort of 100 patients representative of the general population in terms of age, gender, body mass index and blood pressure. Read the complete Blood Pressure Monitoring Journal study here.

"While cuffless blood pressure measurement devices such as dedicated wrist bands and smartwatches exist in the market, but Biospectal is the only validated, software-based smartphone app solution that meets the ISO 81060-2 international protocol for accuracy," said Biospectal CEO and co-founder Eliott Jones. "Biospectal OptiBP makes a huge leap in the ease of blood pressure monitoring and management by enabling convenient, frequent monitoring capability via a smartphone app. As a result, Biospectal OptiBP is well-positioned to become the new essential tool, not only for daily blood pressure monitoring but also for communication with physicians in times of growing telehealth practices."

"The study by the Blood Pressure Monitoring Journal further validates the precision of software-as-a-medical-device technology in a standardized clinical setting, and marks an important milestone to democratize access to blood pressure measurement for hypertensive patients worldwide."

Post this

The Blood Pressure Monitoring Journal study demonstrates the accuracy of the Biospectal OptiBP smartphone app to estimate the blood pressure of participants using a standardized protocol set by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). The study complies with the ISO 81060-2 norm, which establishes a list of standardized criteria to validate the accuracy of a new non-invasive blood pressure measurement device. A comparison was performed between a standard measure (auscultatory blood pressure estimation with a double stethoscope and independent blinded experienced observers) and the cuffless Biospectal OptiBP device to obtain the results. Results demonstrate a mean error of 0.5 ± 7.7 mmHg for systolic and 0.4 ± 4.6 mmHg for diastolic blood pressure, within the ISO 81060-2 norm's allowable ±5 mmHg mean error and standard deviation of ±8 mmHg for systolic and diastolic blood values. As a result, Biospectal OptiBP's performance meets the ISO 81060-2 requirement and demonstrates equivalent performance to the standard inflatable cuff.

According to the World Health Organization, high blood pressure or hypertension is the number one chronic condition and a major cause of premature death worldwide and the most important, modifiable risk factor for cardiovascular disease. Dubbed "the silent killer," hypertension has no noticeable symptoms to indicate something is wrong. Undiagnosed and uncontrolled hypertension are two of the most significant contributing factors to morbidity and mortality. The best ways for patients to protect themselves are being aware of the risks of hypertension and making positive lifestyle changes.

"The study by the Blood Pressure Monitoring Journal further validates the precision of software-as-a-medical-device technology in a standardized clinical setting, and marks an important milestone to democratize access to blood pressure measurement for hypertensive patients worldwide," said Prof. Patrick Schoettker, M.D., Chief Medical Advisor at Biospectal. "Access to smartphone-based solutions to measure blood pressure will allow widespread diagnosis of hypertension and could thereby improve management of hypertensive patients in various settings. This is particularly true in low-income countries where blood pressure devices are scarce, but smartphone penetration is high."

Backed by grants from the Bill & Melinda Gates Foundation and Global Grand Challenges Canada's Saving Lives at Birth initiative, Biospectal also recently launched two global, independent research and validation studies using Biospectal OptiBP. Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal's OptiBP smartphone app and data platform integration with the WHO's Digital Antenatal Care module, following WHO SMART guidelines and built on the WHO Open Smart Register Platform (OpenSRP). Biospectal's patented OptiBP technology was co-developed and clinically validated by the Swiss Center for Electronics and Microtechnology (CSEM). A large-scale, third-party research study published in Scientific Reports in Nature in October 2020 also demonstrated Biospectal's ability to measure blood pressure as accurately as a sphygmomanometer, commonly referred to as a standard blood pressure cuff.

Biospectal OptiBP for Android launched in public beta in early January 2021, and Biospectal OptiBP for iOS launched in alpha in late June 2021. Learn more at https://www.biospectal.com.

About Biospectal
Biospectal is a remote monitoring and biosensing software company focused on the worldwide democratization of clinical monitoring. We make it easy for hypertension patients and health-conscious consumers to take on hypertension - the silent killer and #1 chronic health condition worldwide. Biospectal's OptiBP™ smartphone application and data platform remove the outdated blood pressure cuff barrier and enables frequent and intelligent blood pressure tracking via a fingertip applied to a smartphone camera lens. By optically measuring blood flow through the skin, our proprietary algorithm turns light information into blood pressure values. Anyone with a smartphone can have the convenience of a connected blood pressure monitor with them anytime, anywhere. The captured blood pressure data connects seamlessly with a user's clinicians to support treatment regimens that help improve health, longevity and quality of life.

Founded in July 2017, Biospectal's patented technology was co-developed and clinically validated by the Swiss Center for Electronics and Microtechnology (CSEM) and represents 10+ years of non-invasive optical biosensing R&D. Headquartered in Lausanne, Switzerland, with an additional office in Silicon Valley, Biospectal is a privately held company backed SeedLink, LabCorp, Athensmed and Privilege Ventures. Read our news, follow us on LinkedIn and Twitter, like us on Facebook or learn more at https://biospectal.com.

All trademarks used herein are the property of their respective owners.

Media Contact

Mindy M. Hull, Mercury Global Partners for Biospectal, +1 415-889-9977, [email protected]

Kayla Bortak, Mercury Global Partners for Biospectal, +1 305 697 0027, [email protected]

SOURCE Biospectal

Modal title

Biospectal 's CEO Eliott Jones and Chief Medical Advisor, Prof. Patrick Schoettker, M.D.
Biospectal 's CEO Eliott Jones and Chief Medical Advisor, Prof. Patrick Schoettker, M.D.
Biospectal 's CEO Eliott Jones and Chief Medical Advisor, Prof. Patrick Schoettker, M.D.

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.